- Pyxis Oncology will be responsible for development and
commercialization of BSI-060T (now referred to as PYX-106), a fully
human anti-Siglec-15 monoclonal antibody
- Biosion earns a $10 million
upfront license fee; additional milestone payments and royalties on
commercial sales to be earned upon advancement of PYX-106
NEWARK, Del. and
NANJING, China, March 29, 2022 /PRNewswire/ -- Biosion,
Inc., a global R&D stage biotechnology company, today announced
that Biosion and Pyxis Oncology (NASDAQ: PYXS) have entered
into an agreement under which Pyxis Oncology will be granted an
exclusive license to develop and commercialize Biosion's
anti-Siglec-15 monoclonal antibody, BSI-060T (now referred to as
PYX-106), world-wide, excluding Greater
China. Under the terms of the agreement, Biosion will
receive a $10 million up-front
license fee from Pyxis Oncology. In addition to the up-front
payment, Biosion has the potential to receive significant milestone
payments for PYX-106, totaling up to $222.5
million and single to low double-digit royalties on
commercial sales. Pyxis Oncology plans on submitting the IND for
PYX-106 to the FDA by the second half of 2022 and initiating a
Phase 1 trial shortly thereafter. Under the agreement, Pyxis
Oncology has the opportunity to license additional preclinical
assets that target anti-Siglec-15 using other approaches to
treatment.
"The anti-Siglec 15 monoclonal antibody, PYX-106, is an exciting
addition to the Pyxis Oncology pipeline," said Jay Feingold, MD, PhD, Chief Medical Officer of Pyxis
Oncology. "I believe this potential
best-in-class program will address high unmet medical need in a
variety of solid tumors including non-small cell lung cancer and
head and neck cancer. As an oncologist, my passion has been
advancing potential breakthrough medicines to treat patients with
difficult-to-treat cancers who have little hope in the advanced and
progressive setting."
Biosion continues to deliver breakthrough therapies to address
unmet medical needs of patients worldwide. To accelerate the global
development of its innovative pipeline, Biosion is expanding
worldwide partnerships with leading biotech companies. "The
licensing of our anti-Siglec-15 mAb to Pyxis Oncology for global
development demonstrates the strength of our discovery engine to
generate antibody-based therapeutics with superior
properties," said Mingjiu Chen,
Ph.D., Chief Executive Officer and
founder of Biosion. Dr. Chen continued "Data from anti-Siglec-15
preclinical studies show that BSI-060T has high affinity, high cell
binding and activity, dose-proportional activity on reducing
immunosuppression of Siglec-15 on T cells and long half-life that
will allow BSI-060T to become a best-in-class mAb in the treatment
of solid tumors."
About Biosion, Inc.
Biosion is a global R&D biotechnology company committed to
developing antibody-based therapies to improve patient outcomes for
the treatment of immune and oncologic diseases. Established in
2017, Biosion has built a pipeline of innovative biologics through
its internally derived technologies including the H³ antibody
discovery, SynTracer™ HT-endocytosis and Flexibody™ bispecific
platforms. Biosion's lead asset, BSI-045B (anti-TSLP mAb), is
currently in phase 1 clinical trials for atopic dermatitis and
severe asthma. Biosion and partners have plans to progress
additional assets into the clinic for oncology indications over the
next year. Biosion has operations in the US, Australia, and China. To learn more about Biosion visit
www.biosion.com.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a multi-asset, multi-modality company
focused on defeating difficult to treat cancers and improving
patient lives. By leveraging our fully integrated research,
development and commercial capabilities, our expert team is
efficiently building a diversified portfolio of next-generation
therapeutics. Pyxis Oncology's therapeutic candidates are designed
to directly kill tumor cells, and to address the underlying
pathologies created by cancer that enable its uncontrollable
proliferation and immune evasion. Since its launch in 2019, Pyxis
Oncology has developed a broad portfolio of novel antibody-drug
conjugate product candidates, and monoclonal antibody, or mAb,
preclinical discovery programs that it is developing as
monotherapies and in combination with other therapies. To learn
more about Pyxis Oncology, visit www.pyxisoncology.com.
Media and Investor Contact:
Frank Liu, Ph.D.
Senior Director, Business Development
Biosion USA, Inc.
Phone: +1-302-998-5126
E-mail: Frank.Liu@Biosion.com
View original
content:https://www.prnewswire.com/news-releases/biosion-licenses-bsi-060t-anti-siglec-15-to-pyxis-oncology-301512711.html
SOURCE Biosion, Inc.